Aerin gets new CPT code for endoscopic destruction of the posterior nasal nerve
MOUNTAIN VIEW, Calif., Oct 19: Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with noninvasive solutions for the treatment of chronic nasal conditions, announced that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel accepted the application for a new Category I CPT code to report endoscopic destruction of the posterior nasal nerve using radiofrequency (RF) ablation. This information was released by the AMA in the Summary of Panel Actions from the September CPT Editorial Panel meeting. The new code will become effective on January 1, 2024, and describes the procedure performed by ENT physicians when treating their patients with Aerin Medical’s RhinAer ®. The RhinAer Stylus precisely applies RF energy to overactive nerves in the back of the nose, reducing chronic rhinitis symptoms.
The new code describes the procedure that ENT surgeons perform using RhinAer. RhinAer is a non-invasive, temperature-controlled radiofrequency technology that durably treats the causes of rhinorrhea (runny nose), post-nasal drip and congestion associated with chronic rhinitis in a single session.
“A new CPT code is an important milestone for ENT physicians and their patients, enabling appropriate valuation and improving access to this transformative solution that can be readily performed in the physician office setting,” said Matt Brokaw, CEO of Aerin Medical. “We appreciate the otolaryngology society leadership and physician investigator commitment to generating robust clinical evidence for the RF approach, including the longest-term published randomized controlled trial data available.”
Technology
The company recently announced the launch of a next-generation RhinAer Stylus designed to provide physicians with improved visualization, as well as easier access and tissue apposition, especially in patients with narrow nasal airways.
Using temperature-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea (runny nose) and congestion. RhinAer initially received FDA 510(k) clearance in December 2019 and CE Mark in 2020.
Aerin Medical is a privately held, venturebacked company, with US offices in California and Texas. Aerin’s mission is to provide
ENT physicians with non-invasive solutions for the treatment of chronic nasal conditions. The company’s products, VivAer ® for nasal airway obstruction and RhinAer ® for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with in-office procedures performed with local anesthetic. More than 60,000 patients have been treated with Aerin Medical products to date.